{
    "Trade/Device Name(s)": [
        "CONTOUR\u00ae NEXT GEN Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care US Inc.",
    "510(k) Number": "K223293",
    "Predicate Device Reference 510(k) Number(s)": [
        "K193407"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "October 25, 2022",
    "Summary Letter Received Date": "October 26, 2022",
    "Submission Date": "November 18, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood (fingertip)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "CONTOUR\u00ae NEXT GEN meter",
        "CONTOUR\u00ae Diabetes app"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "Bluetooth Low Energy"
    ],
    "Methodologies": [
        "In vitro quantitative measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "App",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for CONTOUR\u00ae NEXT GEN Blood Glucose Monitoring System for self-testing glucose in capillary whole blood",
    "Indications for Use Summary": "Intended for the quantitative measurement of glucose in fresh capillary whole blood from fingertips by a single person with diabetes for self-testing at home as an aid in monitoring diabetes control, not for diagnosis or screening of diabetes or for neonatal use",
    "fda_folder": "Clinical Chemistry"
}